What is Leerink Partnrs’ Forecast for Illumina Q2 Earnings?

Illumina, Inc. (NASDAQ:ILMN) – Stock analysts at Leerink Partnrs raised their Q2 2026 earnings per share (EPS) estimates for Illumina in a research report issued to clients and investors on Monday, November 17th. Leerink Partnrs analyst P. Souda now expects that the life sciences company will post earnings per share of $1.25 for the quarter, up from their previous forecast of $1.20. The consensus estimate for Illumina’s current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina’s Q3 2026 earnings at $1.41 EPS.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the prior year, the company earned $1.14 EPS. Illumina’s quarterly revenue was up .4% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS.

A number of other research firms also recently issued reports on ILMN. UBS Group boosted their target price on shares of Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Morgan Stanley upped their target price on Illumina from $100.00 to $105.00 and gave the stock an “equal weight” rating in a research note on Monday, August 4th. JPMorgan Chase & Co. boosted their price target on Illumina from $100.00 to $105.00 and gave the company a “neutral” rating in a report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $115.00.

Illumina Stock Up 1.6%

ILMN stock opened at $121.97 on Tuesday. The company has a market capitalization of $18.64 billion, a P/E ratio of 15.44, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. Illumina has a 12 month low of $68.70 and a 12 month high of $153.06. The firm’s fifty day simple moving average is $103.75 and its 200-day simple moving average is $96.73. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 500 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were acquired at an average cost of $122.13 per share, with a total value of $61,065.00. Following the completion of the acquisition, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. This trade represents a 4.16% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.17% of the company’s stock.

Institutional Investors Weigh In On Illumina

Several institutional investors have recently bought and sold shares of the company. Next Capital Management LLC purchased a new position in shares of Illumina in the second quarter valued at approximately $341,000. Andra AP fonden increased its stake in Illumina by 426.3% during the 2nd quarter. Andra AP fonden now owns 102,491 shares of the life sciences company’s stock worth $9,779,000 after buying an additional 83,017 shares during the period. Bourgeon Capital Management LLC lifted its holdings in Illumina by 76.4% during the 2nd quarter. Bourgeon Capital Management LLC now owns 141,896 shares of the life sciences company’s stock worth $13,538,000 after buying an additional 61,468 shares in the last quarter. GC Wealth Management RIA LLC purchased a new position in Illumina in the 2nd quarter valued at approximately $2,289,000. Finally, waypoint wealth counsel purchased a new position in Illumina in the 2nd quarter valued at approximately $321,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.